ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

This study is currently recruiting participants.
Verified by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., August 2008

Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier: NCT00566202
  Purpose

The purpose of this study is to evaluate the safety and effectiveness of JNJ-18038683 compared to escitalopram and placebo in patients with moderate to severe depression.


Condition Intervention Phase
Major Depressive Disorder
Drug: placebo
Drug: JNJ-18038683
Drug: escitalopram
Phase II

MedlinePlus related topics:   Depression   

ChemIDplus related topics:   Escitalopram    Benzetimide    Citalopram    Citalopram hydrobromide    Dexetimide    Escitalopram oxalate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title:   A Phase IIa Multicenter, Randomized, Double-Blind, Double-Dummy, and Placebo- and Active Controlled Study to Investigate the Safety and Efficacy of JNJ-18038683 Administered to Subjects With Major Depressive Disorder

Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Primary Outcome Measures:
  • Explore the effectiveness of JNJ-18038683 in patients with moderate to severe depression as determined by accepted clinical assessments done throughout the study. [ Time Frame: Clinical assessments to evaluate depression will be done 8 times at weekly visits from baseline through the Week 7 visit. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Explore the safety and tolerability of JNJ-18038683 in patients with moderate to severe depression by assessing adverse events, vital signs, laboratory test results, ECGs and physical exams. [ Time Frame: Vital signs will be collected weekly throughout the study; ECGs will be collected at screening, baseline, Wks 3 and 7; Laboratory test will be collected at screening, baseline, and Wks 1,3,5,7 and 8. Adverse Events will be throughout the study. ] [ Designated as safety issue: No ]

Estimated Enrollment:   225
Study Start Date:   November 2007
Estimated Study Completion Date:   February 2009

Arms Assigned Interventions
001: Experimental Drug: JNJ-18038683
10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, placebo daily for 1 week
002: Active Comparator Drug: escitalopram
10 mg daily for 1 week, 20 mg daily for 6 weeks,10 mg daily for 1 week
003: Placebo Comparator Drug: placebo
one dose daily for 8 weeks

Detailed Description:

This study is being done to assess safety and tolerability and to explore the effectiveness of a new, experimental drug in the treatment of moderate to severe depression. Approximately 225 patients with depression will be recruited for the study. Patients who meet study criteria will need to stop taking any depression medications they are currently using. They will be randomly assigned to one of 3 treatment arms; each patient has an equal chance of receiving 20 mg JNJ-18038683, 20 mg escitalopram, or placebo. Placebo has no active drug. Escitalopram is a drug currently approved to treat depression. This is a blinded study, i.e. the patient, the study doctor and the study sponsor will not know what treatment the patient receives until all patients complete the study. Patients receiving either escitalopram or JNJ-18038683 will be titrated up to their assigned dose, receiving 10 mg doses for one week prior to increasing to 20 mg. Patients who are not able to tolerate 20 mg of JNJ-18038683 will be allowed to drop down to the 10 mg dose at any time after the titration period. Patients taking 20 mg escitalopram will receive 10 mg their final week to taper off of the drug. Patients will be dispensed a drug blister card at each weekly visit containing drug for the upcoming week. The study doctor and the sponsor will monitor the study for the occurrence of possible side effects. In addition to a screening visit, patients will return weekly for 9 additional study visits. After completing the study, patients may resume other depression medications. Medical and psychiatric history, physical examination, blood pressure, heart rate, temperature, weight and ECGs will be checked periodically. Blood samples will be taken for standard safety laboratory tests as well as for the measurement of the drug blood level. Questionnaires relating to depression, sleep and sexual experience will be administered throughout the study.

Each day for nine weeks, patients will take orally two JNJ-18038683 tablets, active and/or placebo, and two escitalopram capsules, active and/or placebo.

  Eligibility
Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Diagnosed with moderate to severe major depressive disorder
  • Willing to use acceptable methods of birth control throughout the study and for 3 months after
  • In good general health

Exclusion Criteria:

  • No history or current diagnosis of other psychiatric conditions such as bipolar disorder, psychotic disorder, general anxiety disorder, anorexia, obsessive compulsive disorder, post traumatic stress disorder, antisocial personality disorder, mental retardation, pervasive developmental disorder, or cognitive disorder
  • No history or presence of drug abuse
  • No use of prescription medications or herbal medications other than hormone replacement therapies
  • No prior history of heart disease or current significant blood, lung, kidney, liver, heart, breathing, neurologic or thyroid disorders
  • No patients who are either pregnant or nursing
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00566202

Contacts
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:     info1@veritasmedicine.com    

Show 27 study locations  Show 27 Study Locations

Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Investigators
Study Director:     Alza Corporation Clinical Trial     Alza Corporation, DE, USA    
  More Information


To learn how to participate in this trial please click here.  This link exits the ClinicalTrials.gov site
 

Responsible Party:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C. ( Senior Director Clinical Development )
Study ID Numbers:   alzaCR014617, C-2007-007
First Received:   November 29, 2007
Last Updated:   October 2, 2008
ClinicalTrials.gov Identifier:   NCT00566202
Health Authority:   United States: Food and Drug Administration

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
depressive disorder  
JNJ-18038683  
depression  
escitalopram  

Study placed in the following topic categories:
Depression
Mental Disorders
Mood Disorders
Depressive Disorder, Major
Dexetimide
Depressive Disorder
Citalopram
Serotonin
Behavioral Symptoms

Additional relevant MeSH terms:
Parasympatholytics
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Disease
Molecular Mechanisms of Pharmacological Action
Cholinergic Antagonists
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Psychotropic Drugs
Antiparkinson Agents
Cholinergic Agents
Serotonin Uptake Inhibitors
Pharmacologic Actions
Muscarinic Antagonists
Serotonin Agents
Pathologic Processes
Autonomic Agents
Therapeutic Uses
Peripheral Nervous System Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on October 07, 2008




Links to all studies - primarily for crawlers